Browse by Medical Category
Explore current research projects in the Endocrine Unit at Massachusetts General Hospital or search our open clinical trials and medical research studies.
Research in the Endocrine Unit focuses on metabolic bone diseases and mineral metabolism and ranges from trials of novel therapies for osteoporosis to use of genetically altered mice and cell biology to understand the factors that influence calcium and phosphate metabolism.
The Bastepe Laboratory at Massachusetts General Hospital investigates the role of the GNAS locus and its gene products in physiology and disease pathogenesis.
The Demay Laboratory at Massachusetts General Hospital is focused on understanding the role of the vitamin D receptor (VDR) in skeletal maturation and in cutaneous homeostasis.
The Kobayashi Laboratory at Massachusetts General Hospital investigates the genetics of skeletal development.
The Kronenberg Laboratory at Massachusetts General Hospital uses genetically altered mice to study signaling by the PTH/PTHrP receptor in bone, bone development more generally and the relationships between cells of the osteoblast lineage and hematopoiesis.
Research in the Mannstadt Laboratory at Massachusetts General Hospital focuses on diseases of the parathyroid glands and mineral metabolism.
Thomas Gardella, PhD, is an Assistant Professor in Medicine and Biochemistry in the Massachusetts General Hospital Endocrine Unit, and conducts basic research on parathyroid hormone (PTH) and the PTH receptor.
The Wein laboratory studies molecular mechanisms controlling osteocyte differentiation and function. Our research focuses on transcriptional control of sclerostin, an osteocyte-specific secreted protein that happens to be a drug target for osteoporosis. We are interested in understanding how osteocytes turn on sclerostin, and how signals that boost bone formation (parathyroid hormone, mechanical loading) regulate its expression.
The Eugene Rhee Laboratory is interested in several aspects of renal metabolism, with the goal to understand how alterations in energy metabolism contribute to kidney disease pathogenesis and its complications and to discover metabolite markers of CKD and its progression.
Back to Top